Pulmonx reports Q4 EPS (33c), consensus (45c)

Reports Q4 revenue $23.77M, consensus $22.29M. “Our record quarterly and full year results underscore the continued success of our focused strategy and execution in further expanding our account base, optimizing patient workflows, and raising awareness among both patients and referring physicians,” said Steve Williamson, president and CEO. “With strong underlying demand and ongoing momentum, particularly with the pilot launch of the LungTraX software platform, we are confident in our ability to drive long-term, sustainable growth in 2025 and beyond.”